Relationship Between Dopamine D₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

TLDR

The study aimed to determine whether in vivo dopamine D2 receptor occupancy predicts clinical response, extrapyramidal side effects, and hyperprolactinemia in first‑episode schizophrenia patients treated with haloperidol. In a double‑blind trial, 22 first‑episode schizophrenia patients received 1.0 or 2.5 mg/day haloperidol for two weeks, after which D2 occupancy was measured by [11C]raclopride PET and clinical outcomes were reassessed at four weeks, with dose adjustments for non‑responders. Higher D2 occupancy correlated with greater clinical improvement, hyperprolactinemia, and extrapyramidal side effects, with significant increases above 65%, 72%, and 78% occupancy respectively, supporting a target‑and‑trigger model of antipsychotic action.

Abstract

OBJECTIVE: Since all antipsychotics block dopamine D2 receptors, the authors investigated how well D2 receptor occupancy in vivo predicts clinical response, extrapyramidal side effects, and hyperprolactinemia. METHOD: In a double-blind study, 22 patients with first-episode schizophrenia were randomly assigned to 1.0 or 2.5 mg/day of haloperidol. After 2 weeks of treatment, D2 receptor occupancy was determined with [11C]raclopride and positron emission tomography, and clinical response, extrapyramidal side effects, and prolactin levels were measured. Patients who showed adequate responses continued taking their initial doses, those who did not respond had their doses increased to 5.0 mg/day, and evaluations were repeated at 4 weeks for all patients. RESULTS: The patients showed a wide range of D2 occupancy (38%–87%). The degree of receptor occupancy predicted clinical improvement, hyperprolactinemia, and extrapyramidal side effects. The likelihood of clinical response, hyperprolactinemia, and extrapyramidal side effects increased significantly as D2 occupancy exceeded 65%, 72%, and 78%, respectively. CONCLUSIONS: The study confirms that D2 occupancy is an important mediator of response and side effects in antipsychotic treatment. The data are consistent with a “target and trigger” hypothesis of antipsychotic action, i.e., that the D2 receptor specificity of antipsychotics permits them to target discrete neurons and that their antagonist properties trigger within those neurons intracellular changes that ultimately beget antipsychotic response. While limited to haloperidol, the relationship between D2 occupancy and side effects in this study helps explain many of the observed clinical differences between typical and atypical antipsychotics.